Abstract
To investigate the clinical safety of glucagon for premeditation of upper gastrointestinal endoscopy, effccts of rntramuscural injection of l mg glucagon on blood glucose, ketoneand gastric peristalsis were evaluated in patierlts(n=33)with NIDDM. Patients subjectedto this study were classified into three groups=diet therapy group(n=6)("D"), oralhypoglycemic agent therapy group(n=19)("S")and insulin therapy grou.p(n=8)("I"). Blood glucose(BG)reached its peak value at 60-120minutes after injection ofglucagon. The peak value of BG and increment from FBG to the peak value of BG afterthe injection of glucagon were in order of"1", "S"and"D"groups. Maximum of the peakvalues of BG was 34amg/dl and maximum of the increments was 138mg/dl among the threegroups. An increase of BG after injection of glucagon in patients with FBG aver 150mg/dl ranged from 134 to 178%. Blood ketone at 120minutes after injection of glucagon tendedto decrease in"S"and"I". Gastric peristalsis was inhibited in 69.7%(23/33)of patients at 10 minutes afterinjection of glucagon. These results indicated that there was little possibility of risk of acute diabeticcomplication by glucagon administration in diabetic patients with"good"or"fair"control.Therefore glucagan can be used in safety far the premedicatian of upper gastrointestinalendoscopy in patients with diabetes mellitus.
